PF-08046054  (Synonyms: SGN-PDL1V)

PF-08046054 (SGN-PDL1V) is a PD-L1-directed Antibody-drug conjugate (ADC), which is comprised of an anti-PD-L1 antibody conjugated to VcMMAE (HY-15575). PF-08046054 is direct cytotoxicity to PD-L1-expressing tumor cells via the intracellular delivery of MMAE. PF-08046054 can be used for the study of solid tumors^[1][2]

SG-PDL1V (PF-08046054) exhibits internalization and potent cytotoxic activity against PD-L1-expressing tumor cell lines in vitro^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

SGN-PDL1V (as low as 1 mg/kg; weekly; three doses) achieves tumor regressions in multiple tumor xenograft models^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

150166 (average)

Liquid

Colorless to light yellow

[PF-08046054]

Shipping with dry ice.

-80°C, protect from light

• [1]. Kwan B, et al. 783 SGN-PDL1V, a novel, investigational PD-L1-directed antibody-drug conjugate for the treatment of solid tumors[J]. 2021.

  [2]. Patnaik A, et al. Phase 1 study of SGN-PDL1V, a novel, investigational vedotin antibody–drug conjugate directed to PD-L1, in patients with advanced solid tumors (SGNPDL1V-001, trial in progress)[J]. 2022.